Investment from The Alpha-1 Project

Top line data expected H2 2019

London, 5 November 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, is pleased to announce that the first patient has been dosed in its Phase 2 clinical study of MPH-966 (alvelestat) for the treatment of alpha-1 antitrypsin deficiency (AATD). The study is being conducted in the United States and Europe with top line data expected in H2 2019.

The Company also announced today a collaboration with and investment from the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP). TAP is investing in Mereo’s MPH-966 development programme subject to the Company meeting agreed development milestones. The Company has also agreed to issue warrants to TAP, on future dates, to subscribe for shares in the Company subject to TAP making the agreed investments in the programme with the first such investment milestone being the dosing of the first patient in the MPH-966 development programme.

[Read More...]

Summary: She has become one of the country’s leading advocates on patient-centered drug development and clinical trial design    The Alpha-1 Project (TAP) announces the appointment of Karen Erickson as Chief Operating Officer, a new...

[Read More...]

Apic Bio Launches to Advance First-in-Class Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency (Alpha 1)                       ...

[Read More...]

Fellowship will advance therapeutic strategies for Alpha-1 Antitrypsin DeficiencyCiting “substantial progress” in the first year of a postdoctoral fellowship at the National Institutes of Health’s (NIH) National Center for Advancing Translational Sci...

[Read More...]

Inhibrx’s AAT-Fc therapeutic should benefit patients with enhanced efficacy and less frequent dosing; Alpha-1 Project collaborates with industry to accelerate drug developmentLA JOLLA, CA and MIAMI, FL, September 16, 2015—Inhibrx and The ...

[Read More...]